WHO has just announced a new strategy against Covid-19, encouraging countries to move from emergency mode to long-term prevention and control.

Russia plans to announce the preliminary results of the Sputnik V vaccine test at the end of October, after the first six weeks of follow-up. The global Covid-19 vaccine race is more exciting than ever as Russia has a high chance of becoming the first country to publish data on phase 3 vaccine trials.

Canada has signed agreements with six pharmaceutical companies to own potential Covid-19 vaccine "candidates" in the world. Although they do not know whether these vaccines are effective and safe or not because no "candidates" have been completed yet, the Government of Canada has decided to buy about 20-72 million doses of each type to store. In the event that one, or several "candidates" from the above 6 pharmaceutical companies are not eligible for marketing authorization, the number of doses pre-booked will be lower than expected.

Representatives of the European pharmaceutical management agency said that even with an urgent evaluation of the two leading "candidates", it is difficult to complete it at the end of the year.

The US pharmaceutical company said it would not patent its vaccine trials before the pandemic ended. Moderna's announcement on October 8 is seen as a move to allow other drug manufacturers to develop injections using their technology.

China views the development of the nCoV vaccine as a "key political mission", with four out of 10 "candidates" moving rapidly to end-stage testing. Chinese President Xi Jinping has repeatedly urged the country's scientists to accelerate the research and development of the nCoV vaccine. Chinese medicine makers were also asked to view their work as a "political important task".

RIO DE JANEIRO Larissa Bragança Itaborahy, a Covid-19 patient physician, is one of tens of thousands of people receiving the experimental nCoV vaccine. The reason Dr. Itaborahy (33) volunteered to try the nCoV vaccine from Sinovac, a "candidate" developed by China, is to fight doubts surrounding the safety and effectiveness of clinical trials. . She said that at present the world is not only facing the Covid-19 epidemic but also against the storm of false information.

The second Russian vaccine uses only part of the nCoV protein instead of the whole virus, stimulating the immune system to produce antibodies without side effects. On October 15, Russia approved a second Covid-19 vaccine, called EpiVacCorona, developed by the Vector Institute. The vaccine contains a small portion of the protein of nCoV, called a peptide, that induces an immune response against Covid-19 and promotes the development of immunity.

After being infected with nCoV in March, Michael Reagan completely lost his memories of his 12-day vacation in Paris, even though the trip had only happened a few weeks earlier. "I looked at all my pictures in Paris, trying to remember. We went to a Madonna show, to the Eiffel Tower and to the Tomb. And I don't remember anything, no memories left. "Anyway," said the 50-year-old vascular specialist.

Johnson & Johnson is the second pharmaceutical company after AstraZeneca to stop clinical trials because of volunteers suddenly infected. "Vaccine trial participants' disease symptoms are being reviewed and evaluated by the Independent Data Safety Surveillance Board Ensemble (DSMB), together with the Johnson & Johnson internal safety and clinicians. Adverse factors such as illness, accident or side effects, even severe cases, are part of any clinical study, especially large studies, "said Johnson & Johnson. (J&J) shared on October 12.